pipette
ENEnglish

Small-molecule ACOD1 inhibition attenuates colitis and tumor growth through a shared myeloid mechanism, diverging from genetic deletion

A. E. Papathanassiu, W. Li, K. Gilbo, I. L. Pegg

PreprintAfirmaciones fuertes, leer con cuidadoUso en el mundo real

En palabras de los autores

Aconitate decarboxylase 1 (ACOD1), the enzyme responsible for synthesis of the immunometabolite itaconate, is widely regarded as an anti-inflammatory brake on tissue damage based on Acod1-deficient mice and itaconate supplementation expermiments. ERG344, a small-molecule ACOD1 inhibitor, suppressed itaconate synthesis in endotoxemic mice and in inflamed colonic mucosa and, contrary to genetic-deletion studies, attenuated acute DSS colitis in an ACOD1-dependent manner. ERG344 treatment was associated with reduced influx of immature monocytes early on and accumulation of mature neutrophils. In syngeneic tumor models, ERG344 prolonged survival and increased tumor-infiltrating lymphocytes and antigen-presenting dendritic cells. Across murine and human colitis scRNA-seq datasets and a ten-model syngeneic tumor atlas, ACOD1 marked interferon-stimulated immature monocytes and maturing neutrophils, and tracked with SOD2 and CD274 independently of interferon and NF-{kappa}B signaling. ACOD1 appears to act through a common myeloid recruitment and maturation mechanism, making pharmacological ACOD1 inhibition a viable therapeutic strategy in colitis and cancer.

Resultado principalEl resumen no menciona limitaciones.

Apareció: viernes, 23 de octubre. bioRxiv. Preprint, todavía sin revisión por pares.

DOI: 10.64898/2026.10.17.759827